Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease

Background Gene‐directed enzyme prodrug therapy (GDEPT) based on the E. coli enzyme purine nucleoside phosphorylase (PNP) represents a new approach for treating slow growing tumours like prostate cancer (PCa). Expressed enzyme converts a systemically administered prodrug, fludarabine phosphate, to a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of gene medicine 2004-01, Vol.6 (1), p.43-54
Hauptverfasser:	Martiniello-Wilks, Rosetta, Dane, Allison, Voeks, Dale J., Jeyakumar, Geetha, Mortensen, Elin, Shaw, Jan M., Wang, Xiao Yang, Both, Gerald W., Russell, Pamela J.
Format:	Artikel
Sprache:	eng
Schlagworte:	2-fluoroadenine Adenocarcinoma - genetics Adenocarcinoma - veterinary Adenoviridae Animals Animals, Genetically Modified Antimetabolites, Antineoplastic - metabolism Disease Models, Animal Escherichia coli - enzymology Escherichia coli - genetics Female fludarabine fludarabine phosphate GDEPT Gene therapy Genetic Therapy - methods Infusions, Parenteral Male Mice Mice, Inbred C57BL ovine atadenovirus PNP preclinical studies Prodrugs prostate Prostate - anatomy & histology Prostatic Neoplasms - genetics Prostatic Neoplasms - veterinary Purine-Nucleoside Phosphorylase - genetics Purine-Nucleoside Phosphorylase - pharmacology Survival Analysis TRAMP model Vidarabine Phosphate - analogs & derivatives Vidarabine Phosphate - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!